Imfinzi may be used to treat patients with advanced cancer bladder whose illness has advanced despite chemotherapy. The average wholesale acquisition price for the drug is about $15,000 a month, according to AstraZeneca.
While this decision marks the first approved use for the immunotherapy drug, AstraZeneca is also exploring Imfinzi’s efficacy to treat lung cancer.
More articles on supply chain:
FDA approves new osteoporosis drug
Supply chain tip of the week: Target services — not supplies — for cost savings
FDA approves RFID device to locate breast lumps
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
